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INTRODUCTION: 
Depression is a common mental disorder, 
characterized by sadness, loss of interest or pleasure, 
feelings of guilt or low self-worth, disturbed sleep or 
appetite, low energy and poor concentration.
1
 
Depression has a worldwide prevalence in various 
forms, of 12-20%. The World Health Organization 
(WHO) has ranked depression fourth in a list of the 
most urgent health problems worldwide. 
 
Depression is 
the leading cause of disability as measured by Years 
Lived with Disability (YLDs) and the 4th leading 
contributor to the global burden of disease as measured 
by Disability Adjusted Life Years (DALYs) in 2000. It 
will become the second leading cause of premature 
death or disability worldwide by the year 2020. At its 
worst, it can lead to suicide, a tragic fatality associated 
with the loss of about 850,000 lives every year globally. 
In India the prevalence of depression is 31.2 / 1000 
population.
2
 
 
DIAGNOSTIC CRITERIA:
3
 
           The DSM-IV TR (Text Revision of the Fourth 
Edition of the Diagnostic and Statistical Manual of 
Mental Disorders, 2000) of the American Psychiatric 
Association lists the following criteria, which need to be 
fulfilled to make a diagnosis of a major depressive 
episode.  
A. Five or more of the following symptoms have been 
present during the same 2-week period and represent 
a change from the previous functioning; at least one 
of the symptoms is either  
(1) depressed mood or (2) loss of interest or pleasure. 
     Note: Do not include symptoms that are clearly due to a 
general medical condition, or mood-incongruent 
delusions or hallucinations. 
1) Depressed mood most of the day, nearly every day, 
as indicated by either subjective report (e.g., feels 
sad or empty) or observation made by others (e.g., 
appears tearful). 
     Note: In children and adults, can be irritable mood. 
2) Markedly diminished interest or pleasure in all, or 
almost all activities, most of the day, nearly every 
day (as indicated by either subjective account or 
observation made by others). 
 
 
*Corresponding author: 
Dr. Nagapati. P. Bhat , 
Assistant Professor,  
Department of Pharmacology, Yenepoya Medical College,  
Yenepoya University, Mangalore, India-575018 
Phone number:   09480710120,  
Email:  npbhat17@gmail.com
ABSTRACT 
Depression is considered as an affective disorder characterized primarily by change of mood. It is associated with significant 
socioeconomic problems, morbidity and mortality. The prevalence of major depression in the general population is estimated at 
5% in world population. Prevalence ranges from 9% in ambulatory medical patients to 30% in hospitalized patients. According 
to the World Health report approximately 450 million people suffer from a mental or behavioral disorder, yet only a small 
minority of them receives even the most basic treatment. Currently, the available anti-depressant agents are associated with 
unwanted side effects and have their own limitations. An increasing number of herbal products have been introduced into 
psychiatric practice, as alternative or complementary medicines. The added advantages of indigenous medicinal treatment 
would include its complementary nature to the conventional treatment making latter safer, well tolerated and economical 
remedy for depressive disorders.  
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3) Significant weight loss when not dieting or weight 
gain (e.g., a change of >5% body weight in a month) 
or increase or decrease in appetite nearly every day. 
     Note: In children, consider failure to make expected 
weight gains. 
4)  Insomnia or hypersomnia nearly every day. 
5) Psychomotor agitation or retardation nearly every 
day (observable by others, not merely subjective 
feelings of restlessness or being slowed down). 
6)  Fatigue or loss of energy nearly every day. 
7) Feeling of worthlessness or excessive inappropriate 
guilt (which may be delusional) nearly every day 
(not merely self-reproach or guilt about being sick). 
8) Decreased ability to think or concentrate, or 
indecisiveness, nearly every day (either by 
subjective account or as observed by others). 
9) Recurrent thoughts of death (not just fear of dying), 
recurrent suicidal ideation without a specific plan, or 
a suicide attempt or a specific plan for committing 
suicide. 
B. The symptoms do not meet criteria for a mixed 
episode. 
C. The symptoms cause clinically significant distress or 
impairment in social, occupational or other important 
areas of functioning. 
D. The symptoms are not due to the direct physiological 
effects of a substance (e.g.,   a drug of abuse, a 
medicine) or a general medical condition (e.g., 
hypothyroidism). 
E. The symptoms are not better accounted for by 
bereavement, i.e., after the loss of    a loved one, the 
symptoms persist for longer than 2 months or are 
characterized by marked functional impairment, morbid 
preoccupation with worthlessness, suicidal ideation, 
psychotic symptoms, or psychomotor retardation. 
TYPES OF DEPRESSION:
4 
1. Unipolar depression: - About 80% of cases, in which 
mood swings in one direction only (either depression 
with a feeling of worthlessness or depression with 
groundless irritability). 
2. Bipolar depression (or manic depressive psychoses, 
MDP):- About 20% cases, characterized by cyclic 
manifestation of depression followed by mania. 
MANAGEMENT OF DEPRESSION: 
 Pharmacotherapy: 
Iproniazid a derivative of isoniazid, a non-
selective monoamine oxidase inhibitor (MAO) inhibitor 
was the first antidepressant to be used clinically in the 
mid 1950’s. Subsequently other MAO inhibitors 
phenelzine and isocarboxazid were introduced. 
Tranylcypromine, structurally related to amphetamine 
was first MAO inhibitor unrelated to hydrazine to be 
discovered. Later the selective MAO-A inhibitors like 
clorgyline, moclobemide and MAO-B inhibitors like 
selegiline were introduced.
5
 
In the late 1940s a series of more than 40 
iminodibenzyl derivatives were synthesized for possible 
use as antihistamines, sedatives, analgesics, and anti-
parkinsonism drugs. One of these was imipramine, a 
dibenzazepine compound which was found to have 
remarkable effect on depressed patients.
6
 Following this 
more selective serotonin reuptake inhibitors were 
developed in the early 1970. These developments were 
paralleled by the identification of compounds with 
selectivity for norepinephrine reuptake and along with 
others effective against both serotonin and 
norepinephrine reuptake.
7 
The currently used antidepressant drugs are classified as 
follows:
8 
I. MAOIs 
 Irreversible agents: 
          I. Phenelzine II. Tranylcypromine III. Isocarboxazid 
IV. Selegiline 
 Reversible agents: 
          I. Moclobemide 
II. Reuptake Inhibitors: 
   1. Serotonin and Norepinephrine reuptake 
inhibitors 
 Older agents (TCAs) 
          I. Amitriptyline II. Dothiepin III. Clomipramine IV. 
Imipramine 
 Newer agents (non-TCAs) 
          I. Venlafaxine II. Milnacipran III. Bupropion IV. 
Duloxetine 
     2. Nonselective norepinephrine-reuptake inhibitors 
          I. Desipramine II. Nortriptyline III. Maprotiline 
     3. Selective serotonin-reuptake inhibitors (SSRIs) 
         I. Fluoxetine II. Paroxetine III. Sertraline IV. 
Fluvoxamine V. Citalopram  
        VI. Escitalopram 
    4. Selective norepinephrine-reuptake inhibitors 
(NRIs) 
         I. Reboxetine 
III. Mixed-action newer agents 
         I. Mirtazapine II. Mianserin III. Nefazodone IV. 
Trazodone 
IV. Augmenting or Adjunctive Drugs 
   A. Mood stabilizers 
           I. Lithium II. Lamotrigine III. Valproic acid 
  B. Antipsychotic agents 
 Typical 
           I. Chlorpromazine II. Haloperidol 
 Atypical 
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      I. Clozapine II. Olanzapine III. Risperidone IV. 
Quetiapine V.Aripiprazole  
          VI. Ziprasidone 
   C. Thyroid supplement 
           I. Thyroxin. 
MECHANISM OF ACTION OF VARIOUS 
ANTIDEPRESSANT DRUGS: 
I. MAO Inhibitors: 
Monoamine oxidase inhibitors (MAOIs) were 
the first class of anti depressants in clinical use. These 
drugs reversibly or irreversible block monoamine 
oxidase enzyme. MAO regulates the metabolic 
degradation of catecholamines, serotonin and other 
endogenous amines in the CNS and peripheral tissues. 
Hepatic MAO has a crucial defensive role in 
inactivating circulating monoamines or compounds, 
such as the indirect-acting sympathomimetic tyramine, 
that are ingested or originate in the gut and are absorbed 
into the portal circulation. Inhibition of this enzyme 
system by MAO inhibitors causes a reduction in 
metabolism and a subsequent increase in the 
concentration of biogenic amines. Of the two major 
molecular species, MAO-A preferentially deaminates 
epinephrine, norepinephrine and serotonin whereas 
MAO-B metabolizes phenylethylamine. Dopamine and 
tyramine are metabolized by both MAO isozymes. 
Clorgyline and moclobemide selectively inhibit MAO-
A and selegiline selectively inhibit MAO-B. 
Phenelzine, tranylcypromine and isocarboxazid inhibit 
both MAO-A and MAO-B. Experimentally, selective 
MAO-A inhibitors are thought to be more effective in 
treating major depression than type B inhibitor. 
            MAOIs are not considered to be first-line 
antidepressant medications because of their extensive 
side-effect profile. They have potent hypotensive 
effects. This is particularly important when treating 
elderly patients. Other common side effects are weight 
gain, sedation, insomnia, restlessness and confusion. 
Anorgasmia is fairly common with therapeutic doses of 
some MAOIs. MAOIs may cause dangerous 
interactions with certain foods (cheese reaction) and 
with serotonergic drugs.
9
 
            Despite their side effect profile MAOIs can be 
useful in patients resistant to tricyclic antidepressants.
10
 
MAOIs appear to be superior to tricyclic agents for 
people with depression charecterized by extreme fatigue 
or extreme psychological sensitivity to rejection or 
failed relationships.
11
 Several short acting selective 
inhibitors of  MAO-A e.g.; brofaromine  moclobemide 
and toloxate are being investigated. They are less likely 
to potentiate the pressor action of tyramine and other 
indirect acting sympathomimetic amines than non 
selective irreversible MAO inhibitors. 
II. Reuptake Inhibitors: 
1. Serotonin and Norepinephrine reuptake 
inhibitors:  
 Older agents (TCAs): 
  The tricyclic antidepressants were discovered 
in the 1950s. They are dibenzazepine derivatives. They 
were called tricyclics because their organic chemical 
structure contains three rings-two benzene rings joined 
by a seven-member ring containing nitrogen, oxygen or 
only carbons. Structurally they differ from 
phenothiazines in that the sulphur is replaced by 
ethylene linkage. Imipramine was initially tested as an 
antipsychotic compound (its chemical is closely related 
to the antipsychotic chlorpromazine), but was found to 
have antidepressant and not antipsychotic properties. 
The actions of tricyclic antidepressants include 
inhibiting the reuptake of norepinephrine predominantly 
and variable blockade of serotonin transport.
12 
In 
addition, TCAs have other actions: blockade of 
muscarinic cholinergic receptors, blockade of H1 
histamine receptors and blockade of α-1 adrenergic 
receptors and to some extent α-2 receptors. Initially the 
pre-synaptic α-2 and 5-HT1 are activated by increase 
amount of norepinephrine and serotonin resulting in 
decreased firing of locus ceruleus and raphe neurons.
13
 
On long term administration there is desensitizing of 
these receptors and induction of other adaptive changes 
in the number and sensitivity of pre and post synaptic 
noradrenergic and serotonergic receptors as well as 
amine turnover in brain which leads to enhanced 
noradrenergic and serotonergic transmission. Tricyclic 
antidepressants also block sodium channels in the heart 
and brain, which can cause cardiac arrhythmias and 
cardiac arrest in overdose, as well as seizures. The 
TCAs do not block dopamine transport but they may 
facilitate effects of dopamine indirectly by inhibiting 
the nonspecific transport of dopamine into 
noradrenergic terminals in cerebral cortex. Tricyclic 
antidepressants also can desensitise D2 dopamine 
autoreceptors through uncertain mechanisms and with 
uncertain behavioural contributions.
14
 The tricyclic 
antidepressants are less commonly used as first line 
antidepressants because of their side effect profile. At 
therapeutic doses, all tricyclic antidepressants are 
considered effective in uncomplicated non delusional 
depression. They tend to have dose related side effects 
such as anticholinergic and orthostatic effects, as well 
as sedation, weight gain and sexual dysfunction. In 
addition, tricyclic antidepressant users have a high risk 
of myocardial infarction and arrhythmias. 
 Newer agents (Non Tricyclic agents): 
 Venlafaxine, duloxetine and milnacipran are 
serotonin-norepinephrine reuptake inhibitors which 
inhibit monoamine transporters more selectively than 
tricyclic antidepressants and without the cardiac 
conduction effects that can occur with tricyclic agents.
15
 
Venlafaxine also weakly inhibits dopamine reuptake. It 
is reported to have little affinity for muscarinic, 
histaminergic or α-1 adrenergic receptors in vitro. It has 
faster onset of action with minimal side effects like 
nausea, dizziness, dry mouth, sexual dysfunction and 
rise in blood pressure. Venlafaxine appears to 
demonstrate superior efficacy and higher rates of 
remission in severe depression as compared with either 
SSRI such as fluoxetine or tricyclic antidepressants.
16 
The efficacy of duloxetine is similar to that of the SSRI 
paroxetine and TCAs. 
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Bupropion inhibits both norepinephrine and 
dopamine reuptake, has no direct action on the 
serotonin system. It is similar in efficacy to tricyclic 
antidepressants and SSRIs. Bupropion is associated 
with less nausea, diarrhea, somnolence and sexual 
dysfunction than are SSRIs and constitutes an effective 
alternative, or adjunctive therapy, for patients who do 
not have a response to SSRIs.
17
 Bupropion is effective 
in the management of smoking cessation and may be 
used as a first-line alternative to nicotine replacement 
therapy (NRT) and its action is said to be independent 
of its antidepressant activity. 
2. Nonselective norepinephrine-reuptake inhibitors: 
The tricyclic antidepressants like desipramine, 
nortriptyline and maprotilene block norepinephrine 
reuptake more potently than serotonin uptake. Even 
these are not really selective since they block α-1, H1 
and muscarinic receptors.
18
 
3. Selective serotonin reuptake inhibitors: 
            SSRIs all share the property of blocking the 
action of the pre-synaptic serotonin reuptake pump, 
thereby increasing the amount of serotonin available in 
the synapse and increasing post synaptic serotonin 
receptor occupancy. Increased synaptic availability of 
serotonin stimulates a large number of post synaptic 5-
HT receptor types. Stimulation of 5-HT3 and 5-HT2c 
receptors contributes to nausea and agitation or 
restlessness respectively.
 
 In the serotonin system, 5-
HT1 subtype auto receptors (type 1A and 7 at raphe cell 
bodies and dendrites, type 1D at terminals) suppress 
serotonin neurons in the raphe nuclei of brain stem, 
inhibiting both tryptophan hydroxylase and neuronal 
release of serotonin.
 
 Repeated treatment leads to 
gradual down regulation and desensitization of auto 
receptor mechanisms over several weeks, particularly of 
5-HT1D receptors at nerve terminals leading to increased 
pre-synaptic activity, production and release of 
serotonin. Additional secondary down regulation of 
postsynaptic 5-HT2A receptors may contribute to 
antidepressant effects directly. 
            The antidepressant effects of SSRIs may not 
appear for three to six weeks after initiation of 
treatment. It is proposed that this delay in clinical 
response is due to gradual “down regulation” or 
decrease in some postsynaptic serotonin receptor types 
in response to the increased amount of synaptic 
serotonin available. This may lead to changes in cellular 
protein production and to subsequent effects on 
neuronal protection and development.
19 
            SSRIs are considered as first line agents in the 
treatment of mild to moderate depression because of 
their relative safety and better acceptability. Their main 
advantage is that they produce little or no sedation, do 
not interfere with cognitive and psychomotor function 
or produce anticholinergic side effects.
 
They do not 
cause postural hypotension, do not inhibit cardiac 
conduction and practically have no seizure precipitating 
propensity. They do not produce weight gain. Their 
predominant side effects are gastrointestinal: nausea 
(due to 5-HT3 receptor stimulation). Increased incidence 
of epistaxis and ecchymosis has been reported due to 
interference with platelet functions. SSRIs may cause 
mania when used in patients with undiagnosed bipolar 
depression patients. These drugs can interact with the 
drugs which increase CNS serotonin activity like 
MAOIs, pethidine, two or more SSRIs etc. and may 
cause serotonergic syndrome.
20
 
            All SSRIs if stopped suddenly can produce 
withdrawal symptoms. Longer t1/2 agents like fluoxetine 
cause lesser incidence of these symptoms. 
4. Selective norepinephrine-reuptake inhibitors 
(NRIs):  
Reboxetine is a selective norepinephrine-
reuptake inhibitor with effectiveness similar to that of 
tricyclic antidepressants and SSRIs. 
III. Mixed action newer agents-Atypical 
antidepressants: 
Atypical antidepressants act more selectively 
on 5-HT receptors subtypes as compared to older 
SSRIs. They also have low affinity for muscarinic, 
dopaminergic and H1 histaminic receptors resulting in 
few adverse reactions. 
1. Mirtazapine 
It is a tetracyclic antidepressant that works by 
its central pre-synaptic α2-adrenergic antagonist effects, 
which results in increased release of norepinephrine and 
serotonin. It is also a potent antagonist of 5-HT2 and 5-
HT3 serotonin receptors and H1 histamine receptors and 
a moderate peripheral α1-adrenergic and muscarinic 
antagonist. It does not inhibit the reuptake of 
norepinephrine or serotonin. It is proposed that the 
medication’s antagonism of pre-synaptic α2-receptors 
and 5-HT2A receptors leads to a significant increase in 
noradrenergic neurotransmission. This heightened 
adrenergic neurotransmission, in concert with 
mirtazapine’s action of increasing serotonin release, is 
thought to be responsible for the medication’s 
antidepressant effect. The adverse effects of mirtazapine 
are increase in appetite, weight gain and sedation.
21
 
2. Mianserin: 
It is a tetracyclic antidepressant which blocks 
pre-synaptic adrenergic (α2) receptors and increases the 
turnover of norepinephrine in brain. Its use is restricted 
owing to its propensity to cause bone marrow 
suppression, seizures, sedation and liver dysfunction. 
3. Trazodone and Nefazodone: 
Nefazodone, a phenylpiperazine is structurally 
related to trazodone, have direct agonistic action at 
serotonin 5-HT2A receptors and has serotonin reuptake 
blocking properties. Trazodone has weak inhibitory 
action on serotonin transport and nefazodone also have 
a minor effect on norepinephrine transport which may 
contribute to antidepressant and anxiolytic activity. 
Both drugs also may inhibit pre-synaptic 5-HT1 subtype 
auto-receptors to enhance neuronal release of serotonin, 
though they also exert partial-agonist effects on 
postsynaptic 5-HT1 receptors. They also block cerebral 
α1 and H1 receptors, contributing to its tendency to 
induce priapism and sedation respectively.
 
Nefazodone 
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appears to be useful in postpartum depression, severe 
depression and treatment resistant depression with 
anxiety.
22
 
4. Tianeptine and amineptine: 
Tianeptine sodium and amineptine 
hydrochloride act by increasing (rather than inhibiting) 
the pre-synaptic reuptake of serotonin. They are 
efficacious in anxio-depressive states with 
psychosomatic symptoms and in endogenous 
depression. They cause anticholinergic side effects. 
Postural hypotension, conduction disturbances and 
arrhythmias can occur specially in patients with cardiac 
diseases.
23
 
5. Agomelatine: 
It is the first melatonergic antidepressant, and 
has potent agonist effects at melatonin MT1 and MT2 
receptors and has beneficial effects upon sleep 
disturbances. It also antagonizes the seretonergic 5-
HT2C receptor, which in turn enhances release of 
dopamine and norepinephrine. The melatonergic and 
serotonergic actions both contribute to its antidepressant 
properties.
24
 Agomelatine was approved for use in 
Europe in 2009 but is not approved in the United States. 
IV. Augmenting or Adjunctive Drugs: 
Various medications used in conjunction with 
other antidepressants may help to augment the effect of 
antidepressants. They can also target different 
components of patient’s symptoms (such as delusions) 
or help to prevent a switch to mania. 
A. Mood stabilizers: 
         Patients with mood swings and a strong family 
history of bipolar disorder may meet criteria for bipolar 
II disorder and should be treated with a mood 
stabilizing drug such as lithium, valproate or 
lamotrigine. 
I. Lithium: It alters cation transport across cell 
membrane in nerve and muscle cells and influences 
reuptake of serotonin and/or norepinephrine; 
second messenger systems involving the 
phosphatidyl-inositol cycle are inhibited; 
postsynaptic D2 receptor supersensitivity is 
inhibited. Lithium is an anti-manic agent and, as a 
mood stabilizer, prevents the recurrence of mania 
or depression. It may be superior to placebo for 
bipolar depression but not for major depression. 
Lithium is an effective augmenting agent, and the 
condition of roughly half the patients who do not 
have a response to a single antidepressant improves 
when lithium is added.
25
 
II. Lamotrigine: It is an anticonvulsant and triazine 
derivative which inhibits the release of glutamate 
(an excitatory amino acid) and inhibits voltage 
sensitive sodium channels, which stabilises 
neuronal membranes. Lamotrigine has weak 
inhibitory effect on the 5-HT3 receptor; in vitro 
inhibits dihydrofolate reductase. It is used as an 
augmenting agent in major depressive disorder and 
for treating and preventing depressive relapse in 
bipolar disorder.
26
 
III. Valproic acid: Causes increased availability of 
gamma-aminobutyric acid (GABA), an inhibitory 
neurotransmitter, to brain neurons or may enhance 
the action of GABA or mimic its action at 
postsynaptic receptor sites. Divalproex or valproate 
may prevent a recurrence of bipolar depression.
27
 
B. Antipsychotic agents:  
Treatment guidelines from the American 
Psychiatric Association published in 2000 recommends 
that patients with psychotic depression should receive 
the combination of an antipsychotic plus antidepressant, 
or should be treated with ECT. Typical antipsychotic 
agents (e.g., chlorpromazine, fluphenazine and 
haloperidol) block the dopamine D2 receptor, whereas 
“atypical” antipsychotic agents (e.g., clozapine, 
olanzapine, risperidone, quetiapine, ziprasidone and 
aripiprazole), like nefazodone, act as 5-HT2A 
antagonists. Atypical antipsychotic drugs are also used 
for treatment resistant major depression and bipolar 
depression.
28
 
C. Thyroid supplement:  
Triiodothyronine (T3) has been used as 
augmentation therapy in patients who have not 
responded to initial treatment with antidepressants. In 
Level 3 of the Sequenced Treatment Alternatives to 
Relieve Depression (STAR*D) trial, triiodothyronine as 
well as Lithium were better tolerated. Trials on the use 
of T3 in combination with SSRI for the initial treatment 
of depression, as enhancement therapy to improve 
initial response rates, have produced contradictory 
findings.
29
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Table 1: Dosing and adverse effect profile of antidepressant medications.
30
 
Name Daily 
Dose 
(mg) 
Side Effects Comments 
SSRIs 
Fluoxetine (Prozac)  
Sertraline (Zoloft)  
Paroxetine (Paxil)  
Fluvoxamine (Luvox)  
Citalopram (Celexa)  
Escitalopram (Lexapro)  
10-80 
Headache; nausea and other GIT 
effects; jitteriness, insomnia,sexual 
dysfunction; can affect plasma levels 
of other medicines (except sertraline); 
akathisia rare.  
Once daily dosing, usually in 
A.M.; fluoxetine has very long 
half-life; must not be combined 
with MAOIs.  
TCAs   
Amitriptyline (Elavil)  
Nortriptyline (Pamelor)  
Imipramine (Tofranil)  
Desipramine  
(Norpramin)  
Doxepin (Sinequan)  
Clomipramine (Anafranil)  
150-300  
50-200  
150-300  
150-300  
 
150-300  
150-300  
Anticholinergic (dry mouth, 
tachycardia, constipation, urinary 
retention, blurred vision); sweating; 
tremor; postural hypotension; cardiac 
conduction delay; sedation; weight 
gain.  
Once daily dosing, usually qhs; 
blood levels of most TCAs are 
available; can be lethal in O.D. 
(lethal dose–2g); nortriptyline 
best tolerated, especially by 
elderly.  
Mixed norepinephrine/ 
serotonin reuptake inhibitors  
Venlafaxine (Effexor)  
75-375  Nausea; dizziness; dry mouth; 
headaches; increased blood pressure, 
anxiety and insomnia; lethality.  
Bid-tid dosing (extended 
release available); lower 
potential for drug interactions 
than SSRIs; contraindicated 
with MAOIs. 
Mirtazapine (Remeron)  15-45  Somnolence; weight gain; neutropenia 
rare.  
Once daily dosing.  
Mixed-action drugs 
Bupropion (Wellbutrin)  
250-450  Jitteriness; flushing; seizures in at-risk 
patients; anorexia; tachycardia; 
psychosis.  
Tid dosing, but sustained 
release also available; fewer 
sexual side effects than SSRIs 
or TCAs; may be useful for 
adult ADD.  
Nefazodone (Serzone)  300-600  Sedation; headache; dry mouth; 
nausea; constipation.  
Once daily dosing; no effect on 
REM sleep unlike other 
antidepressants.  
Amoxapine (Asendin)  
 
200-600  Sexual dysfunction.  Lethality in overdose; EPS 
possible.  
MAOIs  
Phenelzine (Nardil)  
Tranylcypromine (Parnate)  
Isocarboxazid (Marplan)  
45-90  
20-50  
 
20-60  
Insomnia; hypotension; anorgasmia; 
weight gain; hypertensive crisis; 
tyramine cheese reaction; lethal 
reactions with SSRIs; serious reactions 
with narcotics.  
May be more effective in 
patients with atypical features 
or treatment refractory 
depression.  
 
CURRENT STATUS OF ANTIDEPRESSANTS: 
The pharmacological therapies in the treatment 
of depression bring acute and sustained remission only 
in a minority of patients. For example recent 
effectiveness trials have shown that only one out of the 
three depressed out-patients receiving first step 
treatment of SSRI achieved remission from depressive 
symptoms. Other large multicenter trials in chronically 
depressed out-patients confirm the modest remission 
rates. A recent meta-analytic study of randomized 
controlled trial (RCT) data by Kirsch et al. effectively 
concluded that the new antidepressant drugs are either 
no better than placebos or only as effective as placebos. 
In 2008 Turner et al. published a study in the New 
England Journal of Medicine showing that the scientific 
journal literature on antidepressants was biased towards 
“favourable” results.31 There is a dire need for 
developing new effective drugs for the treatment of 
depression.  
Neutraceuticals have started gaining much 
attention in today’s world. Many natural products are 
believed to have role in treating diseases and promotion 
of health. The role of neutraceuticals in the treatment of 
depression is also being evaluated.
32 
The small amount 
of controlled clinical research that has been done is 
encouraging with regard to the efficacy of some 
neutraceuticals that have shown benign side effect 
profiles and limited toxicity. In fact, the most 
commonly used neutraceuticals appear to be better 
tolerated than the more standard, conventionally used 
antidepressants, such as SSRIs. Some of these 
nutritional supplements can be used in patients who 
have achieved only partial treatment response to 
standard antidepressant medications and may offer 
additional clinical benefit without increasing the side 
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effect burden.
 
Studies have shown the efficacy of S-
adenosylmethionine (SAMe), St. John’s Wort (SJW) 
and omega-3 fatty acids
 
in the treatment of depression.
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